Capecitabine (X) plus weekly irinotecan (CAPIRI) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): findings from a phase II trial of the Brazilian Oncology Consordium

被引：0
|
作者：
Barrios, Carlos Henrique [1 ]
Viola, Fabiana [1 ]
Coura, Luciana [2 ]
Del Giglio, Auro [3 ]
Malhias, Clarissa [1 ,4 ]
机构：
[1] Hosp Sao Lucas PUC, Porto Alegre, RS, Brazil
[2] InCA Inst Nacl Canc, Rio De Janeiro, Brazil
[3] Hosp Fac Med ABC, Sao Bernardo Do Campo, Brazil
[4] Nucleo Oncol Bahia, Salvador, BA, Brazil
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：89 / 90
页数：2
相关论文
共 50 条
  • [31] Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)
    Salud, A.
    Escudero, P.
    Feliu, J.
    Lopez-Gomez, L.
    Bolanos, M.
    Galan, A.
    Yubero, A.
    Vicent, J. M.
    Losa, F.
    Gonzalez-Baron, M.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 190 - 190
  • [32] Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)
    Cassinello, J.
    Alvarez, J. V.
    Garcia-Lopez, M. J.
    Pujol, E.
    Colmenarejo, A.
    De Segovia, F.
    Marcos, F.
    Filipovich, E.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 199 - 200
  • [33] Efficacy and safety findings from a phase II study of capecitabine (X) as first-line therapy in Japanese patients (pts) with metastatic colorectal cancer (MCRC): comparison with published Western data
    Shinozaki, E.
    Mizunuma, N.
    Shirao, K.
    Doi, T.
    Arai, Y.
    Hyodo, I.
    Yamaguchi, K.
    Tamura, T.
    Takemiya, S.
    Takiuchi, H.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 198 - 198
  • [34] A phase II trial of capecitabine plus irinotecan (XELIRI) in a biweekly schedule in patients with untreated metastatic colorectal cancer (MCRC)
    Garcia Alfonso, Pilar
    Perez-Manga, Gumersindo
    Gonzalez, M. C.
    Lopez, P.
    Gonzalez, E.
    Belon, J.
    Molina, M.
    Pachon, V.
    Iglesias, L.
    Munoz, V.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 119 - 120
  • [35] Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
    Wenhua Li
    Jianming Xu
    Lin Shen
    Tianshu Liu
    Weijian Guo
    Wen Zhang
    Zhiyu Chen
    Xiaodong Zhu
    Jin Li
    [J]. BMC Cancer, 14
  • [36] Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
    Li, Wenhua
    Xu, Jianming
    Shen, Lin
    Liu, Tianshu
    Guo, Weijian
    Zhang, Wen
    Chen, Zhiyu
    Zhu, Xiaodong
    Li, Jin
    [J]. BMC CANCER, 2014, 14
  • [37] Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
    Cupini, S.
    Bursi, S.
    Masi, G.
    Loupakis, F.
    Barbara, C.
    Fornaro, L.
    Allegrini, G.
    Di Marsico, R.
    Andreuccetti, M.
    Falcone, A.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 251 - 251
  • [38] Preliminary results of the association of weekly irinotecan and capecitabine as first line therapy for metastatic colorectal cancer (MCRC)
    Kattan, Joseph
    Farhat, Fadi
    Ghosn, Marwan
    Nasr, Fadi
    Mokaddem, Walid
    Tueini, Elias
    Dagher, Joya
    Younes, Fariha
    Chahine, Georges
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 100 - 100
  • [39] Capecitabine+3-weekly oxaliplatin (XELOX) vs. capecitabine followed by XELOX after progression as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC): A Mexican oncology study group phase III trial
    Rubio, Jaime
    Reyes, Salvador
    Soto, Celia
    Torrecillas, Laura
    Gonzalez, Fernando
    Castruita, Ana
    Cabrera, Paula
    Cervantes, Guadalupe
    Perez, Laura
    Hernandez, David
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 120 - 120
  • [40] Randomised phase III trial comparing irinotecan plus capecitabine (XELIRI Regimen) vs. irinotecan, 5-Fu and folinic acid (Saltz regimen) as first-line treatment in patients (PTS) with metastatic colorectal cancer (MCRC)
    Munoz, Alberto
    Salud, Antonieta
    Garcia Giron, Carlos
    Murias, Adolfo
    Burillo, Miguel A.
    Arizcun, Alberto
    Gutierrez, David
    Pujol, Eduardo
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 120 - 120
12345